Heat Biologics Beneish M Score

HTBX -  USA Stock  

USD 2.90  0.07  2.36%

This module uses fundamental data of Heat Biologics to approximate the value of its Beneish M Score. Heat Biologics M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Please check Heat Biologics Piotroski F Score and Heat Biologics Altman Z Score analysis.

Heat Biologics Beneish M Score 

 
Refresh
Heat Biologics Total Debt is fairly stable at the moment as compared to the past year. Heat Biologics reported Total Debt of 2.13 Million in 2021. Debt Current is likely to rise to about 456.6 K in 2022, whereas Issuance Repayment of Debt Securities is likely to drop (106.4 K) in 2022. Heat Biologics Asset Turnover is fairly stable at the moment as compared to the past year. Heat Biologics reported Asset Turnover of 0.0391 in 2021. Book Value per Share is likely to rise to 6.72 in 2022, whereas EBITDA Margin is likely to drop (10.78)  in 2022.
At this time, it appears that Heat Biologics is an unlikely manipulator. The earnings manipulation may begin if Heat Biologics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Heat Biologics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Heat Biologics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.49
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables
1.09
Asset Quality
1.0
Expense Coverage
1.09
Gross Margin Strengs
0.99
Accruals Factor
1.09
Depreciation Resistance
1.0
Net Sales Growth
0.99
Financial Leverage Condition
0.93

Heat Biologics Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Heat Biologics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Revenues3.4 M3.4 M
Slightly Down
Increasing
Slightly volatile
Selling General and Administrative Expense18.5 M17.2 M
Significantly Up
Increasing
Slightly volatile
Depreciation Amortization and Accretion532 K493.1 K
Significantly Up
Increasing
Slightly volatile
Total Assets154.1 M142.8 M
Significantly Up
Increasing
Slightly volatile
Investments125.1 M116 M
Significantly Up
Increasing
Slightly volatile
Investments Current125.1 M116 M
Significantly Up
Increasing
Slightly volatile
Property Plant and Equipment Net3.7 M3.4 M
Significantly Up
Increasing
Slightly volatile
Trade and Non Trade Receivables219.9 K203.8 K
Significantly Up
Increasing
Slightly volatile
Total Liabilities9.4 M10 M
Notably Down
Increasing
Slightly volatile
Current Assets141.2 M130.9 M
Significantly Up
Increasing
Slightly volatile
Assets Non Current12.9 M12 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities4.8 M4.2 M
Fairly Up
Increasing
Slightly volatile
Liabilities Non Current4.6 M5.8 M
Significantly Down
Increasing
Slightly volatile
Total Debt2.8 M2.1 M
Significantly Up
Increasing
Stable
Debt Current456.6 K444.9 K
Fairly Up
Increasing
Very volatile
Debt Non CurrentM1.7 M
Fairly Up
Increasing
Stable
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile

Heat Biologics Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Heat Biologics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Heat Biologics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Heat Biologics' degree of accounting gimmicks and manipulations.

About Heat Biologics Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation Amortization and Accretion

531,991Share
Heat Biologics Depreciation Amortization and Accretion is fairly stable at the moment as compared to the past year. Heat Biologics reported Depreciation Amortization and Accretion of 493,065 in 2021

Heat Biologics Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Heat Biologics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201720182019202020212022 (projected)
Revenues1.52 M5.79 M3.05 M2.95 M3.39 M3.37 M
Total Assets20.19 M37.76 M25.96 M124.19 M142.82 M154.1 M
Current Assets11.75 M28.71 M15.21 M113.79 M130.86 M141.19 M
Assets Non Current8.44 M9.05 M10.75 M10.4 M11.96 M12.9 M
Total Liabilities14.41 M7.52 M12.8 M8.7 M10.01 M9.39 M
Current Liabilities10.34 M4.87 M8.44 M3.66 M4.21 M4.81 M
Operating Income(13.12 M)(17.46 M)(20.13 M)(24.93 M)(22.43 M)(24.2 M)

About Heat Biologics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Heat Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Heat Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Heat Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patients immune system against cancer through T-cell activation and expansion. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina. Heat Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.

Heat Biologics Investors Sentiment

The influence of Heat Biologics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Heat Biologics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Heat Biologics Implied Volatility

    
  1324.14  
Heat Biologics' implied volatility exposes the market's sentiment of Heat Biologics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Heat Biologics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Heat Biologics stock will not fluctuate a lot when Heat Biologics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Heat Biologics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Heat Biologics' short interest history, or implied volatility extrapolated from Heat Biologics options trading.

Current Sentiment - HTBX

Heat Biologics Investor Sentiment

Most of Macroaxis users are currently bullish on Heat Biologics. What is your judgment towards investing in Heat Biologics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Heat Biologics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Heat Biologics Piotroski F Score and Heat Biologics Altman Z Score analysis. Note that the Heat Biologics information on this page should be used as a complementary analysis to other Heat Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for Heat Biologics Stock analysis

When running Heat Biologics price analysis, check to measure Heat Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heat Biologics is operating at the current time. Most of Heat Biologics' value examination focuses on studying past and present price action to predict the probability of Heat Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Heat Biologics' price. Additionally, you may evaluate how the addition of Heat Biologics to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Is Heat Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Heat Biologics. If investors know Heat Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Heat Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Heat Biologics is measured differently than its book value, which is the value of Heat Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of Heat Biologics' value that differs from its market value or its book value, called intrinsic value, which is Heat Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heat Biologics' market value can be influenced by many factors that don't directly affect Heat Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heat Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Heat Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heat Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.